Medifast, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing also reports fourth-quarter results. Medifast sells weight-management and wellness products, primarily through OPTA VIA and a network of independent Coaches; approximately 92% of revenue came from subscription-based meal-plan orders.
Financial performance
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Revenue | $934.8 million | $713.7 million | +31.0% |
| Gross profit | $697.8 million | $536.9 million | +30.0% |
| Gross margin | 74.6% | 75.2% | -0.6 percentage points |
| SG&A | $563.7 million | $445.8 million | +26.4% |
| Operating income | $134.2 million | $91.0 million | +47.4% |
| Operating margin | 14.4% | 12.8% | +1.6 percentage points |
| Net income | $102.9 million | $77.9 million | +32.0% |
| Diluted EPS | $8.68 | $6.43 | +35.0% |
| Operating cash flow | $145.2 million | $84.3 million | +$60.9 million |
Q4 2020: Revenue was $264.9 million versus $170.6 million in Q4 2019; net income was $28.0 million versus $19.9 million; diluted EPS was $2.36 versus $1.66.
Cash and cash equivalents were $163.7 million at year-end, with investment securities of $10.8 million; combined cash and investments totaled $174.5 million. Working capital was $123.0 million. The filing reports no borrowings; reported liabilities were primarily accounts payable, accruals, and lease obligations, with total lease obligations of $11.2 million. Operating cash flow funded $5.9 million of capital expenditures, dividends, and other financing needs. Cash dividends paid were $53.2 million; dividends declared were $4.52 per share for the year.
Material changes and drivers
- Revenue growth reflected program initiatives that brought more clients onto plans, a shift toward higher-priced OPTA VIA products, and increased Coach productivity. Active earning Coaches rose 39% to 44,200; Q4 revenue per active earning Coach rose 13.4% to $5,932.
- OPTA VIA represented approximately 98% of FY2020 revenue. OPTA VIA-branded products were 83.5% of consumable units sold, up from 76.0% in 2019.
- Gross margin declined because of promotional activity and higher production costs. SG&A increased with sales, principally from higher Coach commissions, while SG&A as a share of revenue fell to 60.3% from 62.5%.
- The effective tax rate rose to 23.4% from 15.6%, in part because of a lower share-based compensation tax benefit and a new valuation allowance.
Outlook, risks, and unusual items
- Management described the Coach-led OPTA VIA model and international expansion as long-term growth priorities, but provided no specific FY2021 revenue or earnings guidance in the supplied filing text.
- The company planned to sunset its Medifast Direct channel and Medifast-branded products by the end of Q2 2021, focusing resources on OPTA VIA.
- Management said COVID-19 had not materially affected FY2020 results and reported no meaningful supply-chain disruption to date. It cautioned that the pandemic’s duration, consumer effects, and eventual impact on operations and liquidity remained uncertain.
- Key risks include regulatory scrutiny of direct selling, Coach earnings and product claims; dependence on retaining and growing Coaches; reliance on third-party suppliers and a single U.S. manufacturing facility; product liability and advertising claims; competition and changing consumer preferences; cybersecurity and privacy; and international expansion risks.
- FY2020 included $5.8 million of professional services related to a Schedule 13D filing and $1.2 million of severance costs following the prior CFO’s departure. Adjusted non-GAAP operating income was $141.2 million and adjusted diluted EPS was $9.14; these exclude those costs and are not GAAP measures.
- Ordinary-course litigation was disclosed; management did not expect it to materially affect results, financial position, or liquidity, while noting outcomes cannot be predicted. The company said it intended to continue quarterly dividends but gave no assurance of future payments.
Important facts for investors to verify
- Whether Coach growth and higher revenue per Coach continue, and whether client retention supports recurring subscription orders.
- Whether gross-margin pressure from promotions and production costs persists as the business scales.
- Execution and financial effects of discontinuing Medifast Direct and its branded products by Q2 2021.
- Direct-selling compliance, Coach marketing claims, and any regulatory or litigation developments.
- Whether cash generation supports dividends and planned investment, given purchase commitments of $41.6 million and lease payments of $11.9 million.
- FY2020 audited financial statements received an unqualified opinion, and management and the auditor reported effective internal control over financial reporting as of December 31, 2020.